Comparing invasive and conservative treatments for cancer patients with non-ST elevation heart attacks

Impact of Treatment Approaches on Mortality in Cancer Patients With Non-ST Elevation Myocardial Infarction: Invasive vs. Conservative Strategies

This study is testing whether invasive or conservative treatments are better for cancer patients who have had a non-ST elevation heart attack.

Quick facts

• Study type: Observational
• Enrollment: 12500 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Academic / other)
• Locations: 1 site (Ankara)
• Trial ID: NCT06702436 on ClinicalTrials.gov

What this trial studies

This observational study examines the effects of invasive versus conservative management strategies in cancer patients who experience non-ST elevation myocardial infarction (non-ST MI). It includes patients aged 18 and older with a confirmed cancer diagnosis who were treated for non-ST MI in a hospital setting. The study aims to assess hospital mortality rates using GRACE scores and analyze various risk factors, such as cancer type and comorbidities, to understand the relationship between cancer and cardiovascular conditions. Patients will be categorized based on the type of intervention they received, either invasive or pharmacological treatment.

Who should consider this trial

Good fit: Ideal candidates for this study are cancer patients aged 18 and older who have been diagnosed with non-ST elevation myocardial infarction.

Not a fit: Patients who may not benefit from this study include those with ST elevation myocardial infarction or severe comorbidities that could confound the outcomes.

Why it matters

Potential benefit: If successful, this study could provide insights into the most effective management strategies for cancer patients experiencing non-ST elevation myocardial infarction, potentially improving patient outcomes.

How similar studies have performed: While there may be studies on myocardial infarction management in general, this specific focus on cancer patients with non-ST elevation MI is relatively novel and underexplored.

Eligibility criteria

Inclusion Criteria:

* Age: Patients aged 18 years and older.
* Diagnosis: Patients with a confirmed cancer diagnosis.
* Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI).
* Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI.
* Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived.

Exclusion Criteria:

* Age: Patients younger than 18 years.
* Non-cancer diagnoses: Patients without a cancer diagnosis.
* ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI).
* Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes.
* Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data).
* Pregnancy: Pregnant patients, as their conditions may complicate the interpretation of results.
* Inability to provide informed consent: Patients unable to provide informed consent (if applicable).

Where this trial is running

Ankara

• Ankara Oncology Training and Research Hospital — Ankara, Turkey (Recruiting)

Study contacts

• Principal investigator: Arif Timuroğlu — ankara oncology trainig and research hospital
• Study coordinator: Arif Timuroğlu, MD

Conditions Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Malignancy; Mortality